Osimertinib Not Yet Recruiting Phase 1 / 2 Trials for Lung Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs
NCT03891615Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer